Oncoustics Founder Ahmed El Kaffas meets with Muhammad Sheikh and team and Fresno Clinical Research Team

Oncoustics is excited to announce its partnership with Fresno Clinical Research Center! FCRC will be our first North American data acquisition center offering valuable biopsy and steatosis data that will aid Oncoustics in the development and deployment of early diagnostic and treatment monitoring of diseases with high unmet clinical need.

FCRC is a privately owned clinical research site that offers leading-edge phase 2 and phase 3 clinical trials particularly related to liver and other digestive diseases. The principal investigator has 18 years’ experience in conducting national and international clinical trials. Over years these clinical trials have benefited hundreds of deserving local valley patients by providing them with state-of-the-art novel treatment options that were otherwise non-existent in the entire Central California Valley.

For further information, please contact:

‍research@fresnocrc.com
(559) 712-6199‬

Dr Sheikh has served as the founding Chief of the Gastroenterology and Hepatology program at UCSF Fresno. He was instrumental in the creation and accreditation of a new gastroenterology division and fellowship program at UCSF Fresno. He is Professor (emeritus) of Clinical Medicine at UCSF. Prior to moving to Fresno, he was Medical Director for Liver Transplant at the University of California Irvine (UCI) Medical Center.

Dr Sheikh is board-certified in Internal Medicine, Gastroenterology and Clinical Nutrition. In addition, he specializes in hepatology and the management of liver diseases, liver transplant evaluation, and the nutritional support of critically ill patients. Dr Sheikh is actively involved in clinical research as it relates to hepatitis C, fatty liver, and hepatic encephalopathy.

Oncoustics (www.oncoustics.com) is a world leader in AI-based ultrasound data extraction enabling real-time imaging and non-invasive diagnosis in the medical market starting with liver disease. Oncoustics’ platform operates in a hardware agnostic fashion, and enables a whole new level of access to care with the benefits of ease of use, affordability, and optimizing current clinical workflow. Using the Oncoustics’ platform, physicians will be able to visualize areas of interest in the liver or prostate, and specifically retrieve analysis from those areas. The Oncoustics’ solution for ultrasound, including liver and prostate applications, will be submitted for regulatory approval in the United States (FDA 510(k)), Canada (Health Canada medical device license) and the European Union (CE Mark).

For further information, please contact:

Beth Rogozinski, CEO
Oncoustics
brogozinski@oncoustics.com
www.oncoustics.com